Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A, as well as VEGF-IO Bispecific / Multiple, a bispecific antibody engages angiogenesis pathway and anti-tumor immune that targets immune checkpoints and analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Indivior (INDV), Aclaris Therapeutics (ACRS) and Com...

Analysts Are Bullish on Top Healthcare Stocks: Indivior (INDV), Aclaris Therapeutics (ACRS)

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics, with a price target of $6.00. Accordi...

LifeSci Capital Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Compass Therapeutics (CMPX), Grace Therapeutics (GRC...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CMPX	$1.84	+2.79%	37.24M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CMPX	$1.84	+2.8%	37.24M
3
4
5
6

CMPX

CMPX

Dividend Overview

Get Compass Therapeutics Inc. Data in Excel

Get Compass Therapeutics Inc. Data in Excel